← Patent-cliff monitor small molecule CAPLYTA LUMATEPERONE TOSYLATE
Loss of exclusivity December 2040 latest FDA-listed patent expiry
Drug detail Brand name CAPLYTA Active ingredient LUMATEPERONE TOSYLATE Strength EQ 42MG BASE Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval December 2019 Marketing status RX
Listed patents Patent Expires Type 11753419 December 2040 product 12410195 December 2040 product 12122792 December 2040 product 12090155 July 2040 product 11980617 October 2039 use U-3940 11690842 August 2039 product 10695345 August 2039 product 12128043 August 2039 product 11806348 August 2039 product 12070459 August 2039 product 12409176 March 2039 use U-4261 9956227 December 2034 use U-2714 10960009 December 2034 use U-814 11026951 December 2034 use U-3274 RE48839 August 2033 use U-814 8598119 December 2029 use U-543 8648077 December 2029 substance, product 9616061 May 2029 product 10117867 May 2029 use U-3271 RE48825 March 2029 substance, product 9586960 March 2029 substance, product 9199995 March 2029 use U-4343 10464938 March 2028 product
Regulatory exclusivity Code Expires M-319 April 2029 I-904 November 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.